Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct;36(10):1629-38.
doi: 10.1007/s00259-009-1129-6. Epub 2009 Apr 22.

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease

Nelleke Tolboom  1 , Maqsood Yaqub, Ronald Boellaard, Gert Luurtsema, Albert D Windhorst, Philip Scheltens, Adriaan A Lammertsma, Bart N M van Berckel
Affiliations

Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease

Nelleke Tolboom et al. Eur J Nucl Med Mol Imaging. 2009 Oct.

Abstract

Purpose: The aim of this study was to assess the test-retest variability of [11C]PIB studies in patients with Alzheimer's disease (AD) and healthy controls using several tracer kinetic models and to assess the suitability of the cerebellum as reference tissue.

Methods: [11C]PIB studies with arterial sampling were performed in eight AD patients and eight healthy controls. Retest scans were performed in six controls and six AD patients. Data were analysed using plasma input and reference tissue models, together with simple ratios.

Results: Test-retest variability was best ( approximately 3%) for SRTM2, a parametric method based on the simplified reference tissue model. Highest values ( approximately 10%) were found for plasma input models. Cerebellar V(T) values did not differ significantly between AD and controls.

Conclusion: Parametric SRTM2 with the cerebellum as reference tissue is the method of choice for quantitative analysis of [11C]PIB PET studies.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Test-retest variability is shown for a VT, b parametric SRTM2 derived BPND + 1 and c SUVr of several regions of interest (ROI): frontal, medial temporal, temporal and parietal cortex, posterior cingulate and global cortical binding. The latter is the volume-weighted average of the previously mentioned regions. In the case of VT, n = 4 and 5 for patients with Alzheimer’s disease (AD) and healthy controls, respectively; in the case of parametric SRTM2 and SUVr, n = 6 for both patient groups. AD: filled columns; healthy controls: open columns
Fig. 2
Fig. 2
Linear regression between 2T4k derived DVR-1 and a SRTM derived BPND and b parametric SRTM2 derived BPND, and c between SRTM and parametric SRTM2 derived BPND, all without fixed intercept. Data are pooled over all subjects and all regions
Fig. 3
Fig. 3
Scatter plots showing the distribution of individual subject 2T4k derived values of a BP2T4k and b VT for cerebellum (squares) and parietal cortex (triangles) using plasma input data of six patients with Alzheimer’s disease (AD) (filled symbols) and seven healthy controls (open symbols). Cerebellar BP2T4k and VT did not differ significantly between AD patients and healthy controls (BP2T4kp = 0.19, VTp = 0.11 ). Compared with controls a twofold increase was found in AD patients in the parietal cortex (BP2T4kp < 0.001, VTp = 0.001)
See this image and copyright information in PMC

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/BF00308809', 'is_inner': False, 'url': 'https://doi.org/10.1007/bf00308809'}, {'type': 'PubMed', 'value': '1759558', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/1759558/'}]}
    2. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–59. doi:10.1007/BF00308809. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1001/archneur.60.12.1685', 'is_inner': False, 'url': 'https://doi.org/10.1001/archneur.60.12.1685'}, {'type': 'PubMed', 'value': '14676042', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14676042/'}]}
    2. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mastwyk M, MacGregor L, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003;60:1685–91. doi:10.1001/archneur.60.12.1685. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.coi.2004.07.012', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.coi.2004.07.012'}, {'type': 'PubMed', 'value': '15342006', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15342006/'}]}
    2. Schenk D, Hagen M, Seubert P. Current progress in beta-amyloid immunotherapy. Curr Opin Immunol 2004;16:599–606. doi:10.1016/j.coi.2004.07.012. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1002/ana.20009', 'is_inner': False, 'url': 'https://doi.org/10.1002/ana.20009'}, {'type': 'PubMed', 'value': '14991808', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14991808/'}]}
    2. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306–19. doi:10.1002/ana.20009. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1038/sj.jcbfm.9600146', 'is_inner': False, 'url': 'https://doi.org/10.1038/sj.jcbfm.9600146'}, {'type': 'PubMed', 'value': '15944649', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15944649/'}]}
    2. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005;25:1528–47. doi:10.1038/sj.jcbfm.9600146. - PubMed

Publication types